Alexander Pisaturo, MD
Physical Medicine & Rehabilitation · Birmingham, ALNPI 1538121553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 24.6% of the total. Reporting peaked in 2019 at $1,043 and has fallen 93.3% since, to $70 in 2025.
Across 166 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$664
- MDD US Operations, LLC$238
- Scilex Pharmaceuticals Inc.$213
- Pfizer$212
- Collegium Pharmaceutical, Inc.$171
- Assertio Therapeutics, Inc.$127
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,695100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $664 |
| MDD US Operations, LLC | 18 | $238 |
| Scilex Pharmaceuticals Inc. | 13 | $213 |
| Pfizer | 12 | $212 |
| Collegium Pharmaceutical, Inc. | 11 | $171 |
| Assertio Therapeutics, Inc. | 12 | $127 |
| Abbott | 10 | $123 |
| SPR Therapeutics, Inc | 2 | $70 |
| Supernus Pharmaceuticals, Inc. | 1 | $59 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Zyla Life Sciences, Inc. | 4 | $54 |
| IBSA Pharma Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $47 |
| Almatica Pharma LLC | 2 | $45 |
| Spinal Simplicity, LLC | 2 | $41 |
| Biodelivery Sciences International, Inc. | 2 | $40 |
| Braeburn Inc. | 2 | $38 |
| Amgen | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Orexo US, Inc. | 2 | $29 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Johnson & Johnson | 1 | $28 |
| Si-bone, Inc. | 2 | $27 |
| Pacira Therapeutics, Inc. | 1 | $26 |
| Atland Pharmaceuticals, LLC | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $22 |
| Medtronic | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Indivior Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Shionogi Inc | 1 | $12 |
| Boston Scientific | 1 | $11 |
| Kaleo, Inc. | 1 | $11 |
How this compares
$2,695 in reported general payments places this provider in the 80th percentile of 104 physical medicine & rehabilitation providers in Alabama.
See all physical medicine & rehabilitation providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 5,684 | $134,128 |
| BelbucaBuprenorphine Hcl | 173 | $113,541 |
| Lidocaine | 443 | $104,966 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 3,486 | $94,147 |
| Buprenorphine | 308 | $82,197 |
| Gabapentin | 3,191 | $52,829 |
| ZtlidoLidocaine | 48 | $48,797 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 261 | $47,770 |
| Xtampza ErOxycodone Myristate | 91 | $46,296 |
| OxycontinOxycodone Hcl | 80 | $44,126 |
| UbrelvyUbrogepant | 23 | $29,542 |
| Pregabalin | 1,562 | $29,390 |
| BotoxOnabotulinumtoxina | 14 | $25,968 |
| Nurtec OdtRimegepant Sulfate | 20 | $25,733 |
| MovantikNaloxegol Oxalate | 57 | $23,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta | $171 | $180,061295 claims |
| AbbVieUbrelvy, Botox, Linzess, Savella | $664 | $68,09860 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $213 | $48,79748 claims |
| PfizerNurtec Odt | $212 | $25,73320 claims |
| Indivior Inc.Suboxone | $17 | $7,03513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 104 physical medicine & rehabilitation providers in Alabama.
Other physical medicine & rehabilitation in Birmingham
- Don McCormickBirmingham$22K
- Bradly GoodmanBirmingham$15K
- Nelson Santos AgostoBirmingham$14K
- John PantuoscoBirmingham$12K
- Ross LumsdenBirmingham$11K
- Matthew BerkeBirmingham$6K
- Chong WengBirmingham$4K
- Kenneth SmithBirmingham$4K
- Srinivas MallempatiBirmingham$3K
- Aaron GreenbergBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.